Gerium Medical

Noninvasive Bilirubin Measurement Device

Health Tech & Life Sciences

Acquired (Inactive) by Mennen Medical group on Jun 2015 - closed due to acquisition

Company Overview

Snapshot

Founded in January 2011 by Moshe Gerber, Gerium Medical operated with 1–10 employees. The company secured $550,000 across three funding rounds from three investors. In June 2015, Gerium Medical was acquired by Mennen Medical group.

Business overview

Gerium Medical develops BiliCare, a noninvasive bilirubin meter for newborns, leveraging spectroscopy to measure transcutaneous bilirubin levels. This technology involves transmitting light at varying wavelengths through a newborn's ear and calculating bilirubin absorption. The device, which is CE-marked, is designed for neonatal jaundice diagnoses and serves the healthcare sector, specifically hospitals and providers, within the Health Tech & Life Sciences industry.

Company Intelligence Q&A

What is Gerium Medical's primary product?: Gerium Medical's primary product is BiliCare, a noninvasive bilirubin meter designed for newborns to diagnose neonatal jaundice.
When was Gerium Medical founded?: Gerium Medical was founded in January 2011.
Who is a co-founder of Gerium Medical?: Moshe Gerber is a co-founder of Gerium Medical.
Which investor participated in Gerium Medical's funding rounds?: Finaves S.C.R. participated in Gerium Medical's funding rounds in August 2011 and December 2011.

External links

Gerium Medical — full profile (machine-readable)

Gerium Medical is the developer of BiliCare, a noninvasive bilirubin meter for newborns.BiliCares technology is based onspectroscopy, and involves measuring substances using visible and non-visible light at varying wavelengths. The device is CE-marked and used for neonatal jaundice diagnoses. The BiliCare meter measures the level of transcutaneous bilirubin in newborns by transmitting light at different wavelengths through the newborns ear and then measuring the intensity of the wavelengths when they exit the ear. The amount of light absorbed by bilirubin is calculated by comparing the intensity of the light before it enters the tissue with its intensity after it leaves. The transcutaneous bilirubin of the newborn is then calculated according to a customized algorithm. Gerium Medical was acquired by Redworth Israel Ltd in 2015 and is now operating under Mennen Medical Group.

Facts
Name	Gerium Medical
One-liner	Noninvasive Bilirubin Measurement Device
Type	Startup
Primary sector	Health Tech & Life Sciences
Founded	2011
Employees	1-10
Employees (exact)	2
HQ / location	Yavne, HaKishon St 6, Yavne, Israel, Center District
Product stage	Released
LinkedIn	https://www.linkedin.com/company/1418957
IL Registrar	514554534

Facts

Name

Gerium Medical

One-liner

Noninvasive Bilirubin Measurement Device

Type

Startup

Primary sector

Health Tech & Life Sciences

Founded

2011

Employees

1-10

Employees (exact)

HQ / location

Yavne, HaKishon St 6, Yavne, Israel, Center District

Product stage

Released

https://www.linkedin.com/company/1418957

IL Registrar

514554534

Classification
Sectors	Health Tech & Life Sciences, Medical Devices, Diagnostics Devices
Core technology	Sensing
Target customers	Consumers, Demographics & Family, Babies, Parents, Healthcare & Life Sciences, Healthcare, Providers
Business models	B2B
Tags	babies, spectroscopy, measurements, diagnostics, medical-devices, non-invasive, hospitals, real-time, sensors

Classification

Sectors

Health Tech & Life Sciences, Medical Devices, Diagnostics Devices

Core technology

Sensing

Target customers

Consumers, Demographics & Family, Babies, Parents, Healthcare & Life Sciences, Healthcare, Providers

Business models

B2B

Date	Round	Amount	Investors
Dec 2011	B Round	Undisclosed	Finaves S.C.R.
Aug 2011	A Round	Undisclosed	Finaves S.C.R.
Apr 2011	Seed	$550K	Office of the Chief Scientist, Naiot Venture Accelerator

Gerium Medical

Company Overview

Snapshot

Business overview

Company Intelligence Q&A

External links

Generate Slim Page